Saga inks assay development deal with AstraZeneca

2019 04 18 23 19 1417 Hands Shaking V3 400

Swedish liquid biopsy and genomic testing provider Saga Diagnostics is developing new digital polymerase chain reaction (dPCR) assays for AstraZeneca.

Under the deal, Saga will create unique versions of its Sagasafe dPCR assays toward undisclosed methylated targets for analyses of tissue samples and liquid biopsies, according to the company. AstraZeneca will utilize the assays in a clinical research study.

Page 1 of 22
Next Page